IAS-USA Releases 2024 Recommendations for HIV Treatment and Prevention
On the occasion of World AIDS Day on 1 December 2024, the International Antiviral Society-USA (IAS-USA) has published new international guidelines for the treatment and prevention of HIV. The findings are published in JAMA Network. The updated recommendations were developed by a panel of volunteer medical experts.
An international panel of leading experts in HIV research and clinical care identified and reviewed the latest evidence from peer-reviewed literature and conference presentations published between June 2022 and October 2024, as well as data provided by antiretroviral manufacturers. Here is an overview of the recommendations for HIV treatment, prevention and care.
Tailored antiretroviral therapy
The panel recommends that antiretroviral therapy should be tailored to the individual's needs, especially for those who cannot tolerate certain HIV drugs. Long-acting injectable therapies are highlighted as a valuable option to help patients adhere to their treatment plans.
HIV prevention strategies
For people at increased risk of HIV exposure, the guidelines emphasise the use of pre-exposure prophylaxis, available as daily oral medication or long-acting injectable options. In addition, doxycycline is recognised as an effective post-exposure prophylaxis to prevent sexually transmitted infections.
Comprehensive care for people living with HIV
The panel stresses the importance of a holistic approach to HIV care. This includes prevention of cardiovascular disease, management of substance use disorders and monitoring of weight changes that may occur during antiretroviral therapy.
Addressing disparities in access to care
Recognising persistent inequities in access to HIV care and prevention, the guidelines recommend targeted solutions to address gaps in underserved communities. Suggested interventions include: expanding access to video telemedicine and mobile health units; using smartphone reminders for medication or injections; and providing adherence support through traditional methods such as pill boxes and regular check-ins by phone or text.
Reference: Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel. JAMA. Published online December 01, 2024. doi:10.1001/jama.2024.24543
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.